Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
Kabir Mody, Prerna Jain, Sherif El-Refai, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
The Lancet (2023) Vol. 401, Iss. 10391, pp. 1853-1865
Open Access | Times Cited: 504
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 21
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 29
Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging
Marina Baretti, Soumya Shekhar, Vaibhav Sahai, et al.
Hepatology Communications (2025) Vol. 9, Iss. 3
Open Access | Times Cited: 1
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102649-102649
Open Access | Times Cited: 21
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Rei Kudo, Anton Safonov, Catherine Jones, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1919-1935.e9
Open Access | Times Cited: 8
Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring
Woo Jin Choi, Tommy Ivanics, Annabel Gravely, et al.
Annals of Surgical Oncology (2023) Vol. 30, Iss. 6, pp. 3849-3863
Closed Access | Times Cited: 13
Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma
Naoshi Nishida, Tomoko Aoki, Masahiro Morita, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2379-2379
Open Access | Times Cited: 12
Immunotherapy for the treatment of biliary tract cancer: an evolving landscape
H. Catherine Wilbur, Nilofer S. Azad
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 4
The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma
Abdullah Esmail, Mohamed Badheeb, Batool Wael Alnahar, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 910-910
Open Access | Times Cited: 4
A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada
Ravi Ramjeesingh, Prosanto Chaudhury, Vincent C. Tam, et al.
Current Oncology (2023) Vol. 30, Iss. 8, pp. 7132-7150
Open Access | Times Cited: 10
Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review
Matthew J. Hadfield, Kathryn DeCarli, Kinan Bash, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 543-543
Open Access | Times Cited: 10
Molecular Profiling of Biliary Tract Cancers in African American and Caucasian Patients
Zishuo Ian Hu, Dean C. Pavlick, Jeffrey S. Ross, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies
Antonella Cammarota, Rita Balsano, Tiziana Pressiani, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 272-272
Open Access
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Younghoon Kim, Jaewon Song, Namkyoung Kim, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies
Daisaku Yamada, Shogo Kobayashi, Yuichiro Doki, et al.
International Journal of Clinical Oncology (2025)
Open Access
Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma
M. Silvestri, Trung Nghia Vu, Federico Nichetti, et al.
Cancer Medicine (2023) Vol. 12, Iss. 8, pp. 10156-10168
Open Access | Times Cited: 9
Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives
Belén Toledo, Chiara Deiana, Fabio Scianò, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 323-347
Open Access | Times Cited: 3
KRAS Allelic Variants in Biliary Tract Cancers
Gordon Taylor Moffat, Zishuo Ian Hu, Funda Meric‐Bernstam, et al.
JAMA Network Open (2024) Vol. 7, Iss. 5, pp. e249840-e249840
Open Access | Times Cited: 3
HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers
Charalampos Theocharopoulos, Ioannis A. Ziogas, Benedetto Mungo, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104655-104655
Closed Access
Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial
Xubiao Wei, Yabo Jiang, Jinxue Zhou, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review)
Siqi Yang, Rui-Qi Zou, Yu-Shi Dai, et al.
International Journal of Oncology (2023) Vol. 63, Iss. 6
Open Access | Times Cited: 8
Targeted therapies in advanced biliary tract cancers—a narrative review
Michael LaPelusa, Thatcher Heumann, Laura W. Goff, et al.
Chinese Clinical Oncology (2023) Vol. 12, Iss. 2, pp. 14-14
Open Access | Times Cited: 7
Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin
Ugo Testa, Elvira Pelosi, Germana Castelli
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 6
Facts and Hopes in the Systemic Therapy of Biliary Tract Carcinomas
Ángela Lamarca, Teresa Macarulla
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3688-3696
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top